Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00493181 | Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients | completed | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 20, 2012 | clinicaltrials |
| NCT00890656 | Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage | completed | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 20, 2012 | clinicaltrials |
| Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) |
| completed |
| Phase 2 |
| 80 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Feb 20, 2012 |
| clinicaltrials |
| NCT01534702 | Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML(CIARA) | unknown | Phase 1 / Phase 2 | 60 | Hannover Medical SchoolOTHER | 1 | Feb 20, 2012 | clinicaltrials |
| NCT00764829 | Blood Samples to Evaluate Biomarkers of Donor Chimerism | completed | — | 80 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2012 | clinicaltrials |
| NCT01180426 | Extension Study With Tosedostat in Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 2 | 30 | Chroma TherapeuticsINDUSTRY | 1 | Feb 15, 2012 | clinicaltrials |
| NCT00289549 | Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 8 | BioCryst PharmaceuticalsINDUSTRY | 1 | Feb 8, 2012 | clinicaltrials |
| NCT00493129 | Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) | completed | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 8, 2012 | clinicaltrials |
| NCT00764231 | A Study of a Home-based Exercise Intervention for Patients With Acute Myeloid Leukaemia (AML) | completed | Phase 2 | 40 | Toronto Rehabilitation InstituteOTHER | 1 | Feb 8, 2012 | clinicaltrials |
| NCT00124748 | Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)(TOPS) | terminated | Phase 3 | 476 | Novartis PharmaceuticalsINDUSTRY | 6 | Feb 3, 2012 | clinicaltrials |
| NCT00144677 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00144703 | Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation | completed | Phase 2 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 26, 2012 | clinicaltrials |
| NCT00286845 | Use of the MiCK Assay for Apoptosis in AML | completed | — | 50 | Pierian BiosciencesINDUSTRY | 1 | Jan 26, 2012 | clinicaltrials |
| NCT01456182 | Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | Afexa Life Sciences IncINDUSTRY | 1 | Jan 25, 2012 | clinicaltrials |
| NCT00419081 | Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens | terminated | Phase 2 | 100 | BioCryst PharmaceuticalsINDUSTRY | 1 | Jan 23, 2012 | clinicaltrials |
| NCT00640523 | Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 23 | BioCryst PharmaceuticalsINDUSTRY | 2 | Jan 23, 2012 | clinicaltrials |
| NCT00795548 | Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation | completed | Phase 2 | 30 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Jan 23, 2012 | clinicaltrials |
| NCT00088231 | PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP | completed | Phase 1 / Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 20, 2012 | clinicaltrials |
| NCT00289562 | Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 20 | BioCryst PharmaceuticalsINDUSTRY | 1 | Jan 20, 2012 | clinicaltrials |
| NCT01513109 | Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia(ASCI) | unknown | Phase 1 / Phase 2 | 20 | Jules Bordet InstituteOTHER | 1 | Jan 20, 2012 | clinicaltrials |
| NCT01513603 | Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia | unknown | Phase 2 | 50 | New York Medical CollegeOTHER | 1 | Jan 20, 2012 | clinicaltrials |
| NCT00095381 | Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia | completed | Phase 2 | 20 | BioCryst PharmaceuticalsINDUSTRY | 2 | Jan 19, 2012 | clinicaltrials |
| NCT00446303 | A Phase II Study of Maintenance With Azacitidine in MDS Patients | terminated | Phase 2 | 39 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Jan 19, 2012 | clinicaltrials |
| NCT01509300 | HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors | unknown | Phase 1 / Phase 2 | 10 | Asan Medical CenterOTHER | 1 | Jan 13, 2012 | clinicaltrials |
| NCT00723346 | Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia(GRASPALL) | completed | Phase 1 / Phase 2 | 25 | ERYtech PharmaINDUSTRY | 1 | Jan 11, 2012 | clinicaltrials |
| NCT00758693 | Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL) | withdrawn | Phase 2 | 0 | University of KentuckyOTHER | 1 | Jan 11, 2012 | clinicaltrials |
| NCT00766311 | Aerobic and Strengthening Exercise for Acute Leukemia(XRCISL) | completed | N/A | 20 | St. Jude Children's Research HospitalOTHER | 1 | Jan 9, 2012 | clinicaltrials |
| NCT00504491 | R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia(R-CHOP) | withdrawn | Phase 2 | 0 | CABYCINDUSTRY | 1 | Dec 30, 2011 | clinicaltrials |
| NCT00473551 | Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2011 | clinicaltrials |
| NCT00538278 | Prospective Database for Acute Myeloblastic Leukemia | unknown | N/A | 2,000 | King Faisal Specialist Hospital & Research CenterOTHER | 0 | Dec 13, 2011 | clinicaltrials |
| NCT00538447 | Prospective Database for Chronic Myelogenous Leukemia | unknown | N/A | 2,000 | King Faisal Specialist Hospital & Research CenterOTHER | 0 | Dec 13, 2011 | clinicaltrials |
| NCT01310946 | Establishment of Acute Lymphocytic Leukemia Data Base in the Department of Oncology | unknown | — | 203 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Dec 13, 2011 | clinicaltrials |
| NCT00006379 | Non-Ablative Allo HSCT For Hematologic Malignancies or SAA | completed | Phase 2 | 58 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 8, 2011 | clinicaltrials |
| NCT00895297 | Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia(Dasatinib) | terminated | Phase 2 | 50 | European Society for Blood and Marrow TransplantationNETWORK | 4 | Dec 7, 2011 | clinicaltrials |
| NCT01127542 | RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial(RESPeCT) | terminated | Phase 2 | 1 | The Christie NHS Foundation TrustOTHER | 1 | Dec 5, 2011 | clinicaltrials |
| NCT00436904 | Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia | completed | Phase 2 | 30 | Mayo ClinicOTHER | 1 | Dec 1, 2011 | clinicaltrials |
| NCT00002456 | Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation | completed | Phase 3 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00002553 | Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer | completed | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00003887 | Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00005854 | Bone Marrow Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00027547 | Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 2 | Nov 30, 2011 | clinicaltrials |
| NCT00089050 | Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00093366 | Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 32 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00244829 | Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT01227135 | Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia | unknown | Phase 2 | 66 | Lynn McMahonOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT01374139 | Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects | completed | Phase 1 | 88 | PfizerINDUSTRY | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00003874 | Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 29, 2011 | clinicaltrials |
| NCT00110058 | Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 40 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 17, 2011 | clinicaltrials |
| NCT01470924 | Acute Lymphoblastic Leukemia Relapse in Sweden 2003-2007 | completed | — | 76 | Region Örebro CountyOTHER | 1 | Nov 11, 2011 | clinicaltrials |
| NCT00078234 | Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 25 | Genta IncorporatedINDUSTRY | 1 | Nov 7, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Feb 20, 2012source: clinicaltrials